Home › Funds › Propel Bio Management, LLC › PHAT
Propel Bio Management, LLC position in PHAT
PHATHOM PHARMACEUTICALS INC · Health Care
Propel Bio Management, LLC reported holding 1,105,913 shares of PHAT (PHATHOM PHARMACEUTICALS INC) in its Q3 2026 13F filing — a position valued at US$8.1M, representing 4.28% of its reported portfolio and ranking #8 among its reported holdings. Propel Bio Management, LLC has disclosed PHAT holdings in 12 of the last 12 reported quarters, going back to Q4 2023.
Last updated: 2026-11-13 · Source: SEC EDGAR Form 13F-HR
How Propel Bio Management, LLC's PHAT position evolved
Propel Bio Management, LLC first disclosed a stake in PHAT in Q4 2023 at 443,047 shares (US$4.0M). The position peaked in Q3 2024 at 869,927 shares, worth US$15.7M. Across 12 filings, Propel Bio Management, LLC increased the stake 7 time(s), trimmed it 2 time(s) and left it unchanged 2 time(s). The most recent filing (Q3 2026) shows 1,105,913 shares valued at US$8.1M — an increase of 55,555 shares quarter over quarter.. Notable position changes include a 96% increase in Q1 2024 (shares fell 3% over the following quarter), a 40% trim in Q3 2025 (shares rose 41% over the following quarter), a 34% increase in Q4 2025 (shares fell 33% over the following quarter).
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q4 2023 | 443.05K | $4.05M | New |
| Q1 2024 | 869.93K | $9.24M | Add |
| Q2 2024 | 869.93K | $8.96M | Hold |
| Q3 2024 | 869.93K | $15.73M | Hold |
| Q4 2024 | 989.93K | $8.04M | Add |
| Q1 2025 | 1.13M | $7.12M | Add |
| Q2 2025 | 922.93K | $8.85M | Reduce |
| Q3 2025 | 552.93K | $6.51M | Reduce |
| Q4 2025 | 740.92K | $12.29M | Add |
| Q1 2026 | 841.27K | $9.35M | Add |
| Q2 2026 | 1.05M | $11.40M | Add |
| Q3 2026 | 1.11M | $8.07M | Add |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About PHAT and 13F data
PHAT (PHATHOM PHARMACEUTICALS INC) is a Health Care company. 29 other funds we track also report a position in PHAT — the largest reported positions include Frazier Life Sciences Management, L.P. (US$135.3M), Medicxi Ventures Management (Jersey) Ltd (US$54.5M), Carlyle Group Inc. (US$25.5M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding PHAT
- Frazier Life Sciences Management, L.P. 12.47M sh · $135.26M · Q2 2026
- Medicxi Ventures Management (Jersey) Ltd 7.46M sh · $54.49M · Q3 2026
- Carlyle Group Inc. 3.50M sh · $25.53M · Q3 2026
- NEA Management Company, LLC 1.96M sh · $21.27M · Q2 2026
- 683 Capital Management, LLC 1.85M sh · $20.07M · Q2 2026
- Catalys Pacific, LLC 1.88M sh · $13.74M · Q3 2026
- EcoR1 Capital, LLC 625.00K sh · $6.78M · Q2 2026
More on Propel Bio Management, LLC
FAQ
How long has Propel Bio Management, LLC held PHAT?
Propel Bio Management, LLC has disclosed PHAT holdings in 12 of the last 12 reported quarters, going back to Q4 2023.
What is Propel Bio Management, LLC's current position in PHAT?
As of Q3 2026, Propel Bio Management, LLC holds 1.11M shares of PHAT (PHATHOM PHARMACEUTICALS INC), valued at $8.07M, representing 4.28% of its reported portfolio and ranking #8.
Has Propel Bio Management, LLC been buying or selling PHAT?
In the latest 13F filing (Q3 2026), Propel Bio Management, LLC increased its position in PHAT. The position peaked in Q3 2024 at 869.93K shares.
Which other funds hold PHAT?
Other major institutional holders of PHAT include Frazier Life Sciences Management, L.P., Medicxi Ventures Management (Jersey) Ltd, Carlyle Group Inc., among 29 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.